S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)

CymaBay Therapeutics Stock Price, News & Analysis (NASDAQ:CBAY)

$20.49
+0.07 (+0.34%)
(As of 10:04 AM ET)
Compare
Today's Range
$20.23
$20.76
50-Day Range
$12.63
$20.42
52-Week Range
$3.83
$21.06
Volume
74,205 shs
Average Volume
1.90 million shs
Market Capitalization
$2.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.27

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.08 Rating Score
Upside/​Downside
9.1% Upside
$22.27 Price Target
Short Interest
Bearish
10.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
-0.01mentions of CymaBay Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$3.09 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.94) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

804th out of 949 stocks

Pharmaceutical Preparations Industry

365th out of 421 stocks


CBAY stock logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CBAY Stock Price History

CBAY Stock News Headlines

CymaBay Therapeutics (NASDAQ:CBAY) Hits New 1-Year High at $19.79
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
CymaBay Therapeutics (NASDAQ:CBAY) Trading 5.3% Higher
CBAY CymaBay Therapeutics, Inc.
Circling Back On CymaBay Therapeutics
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
CymaBay Therapeutics Inc CBAY
Recap: CymaBay Therapeutics Q3 Earnings
Piper Sandler Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)
Where CymaBay Therapeutics Stands With Analysts
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.27
High Stock Price Target
$34.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+9.1%
Consensus Rating
Buy
Rating Score (0-4)
3.08
Research Coverage
12 Analysts

Profitability

Net Income
$-106,000,000.00
Pretax Margin
-290.50%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.43 per share

Miscellaneous

Free Float
105,465,000
Market Cap
$2.32 billion
Optionable
Optionable
Beta
0.34
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Sujal A. Shah (Age 50)
    President, CEO & Director
    Comp: $1.04M
  • Dr. Charles A. McWherter Ph.D. (Age 68)
    President of Research & Development and Chief Scientific Officer
    Comp: $700.65k
  • Mr. Paul T. Quinlan (Age 60)
    General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $629.72k
  • Mr. Harish Shantharam C.F.A.
    Chief Financial Officer
  • Mr. Ken Boehm
    Senior Vice President of Human Resources
  • Mr. Patrick J. O'Mara (Age 62)
    Senior Vice President of Business Development
  • Dr. Robert L. Martin (Age 61)
    Senior Vice President of Manufacturing & Nonclinical Development
  • Ms. Klara A. Dickinson-Eason (Age 55)
    Chief Regulatory & Quality Assurance Officer
    Comp: $441.84k
  • Ms. Becki Filice (Age 62)
    Senior Vice President of Portfolio & Product Leadership
  • Mr. Lewis J. Stuart B.A. (Age 64)
    M.B.A., Chief Commercial Officer
    Comp: $378.79k














CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price target for 2024?

12 analysts have issued 12-month target prices for CymaBay Therapeutics' stock. Their CBAY share price targets range from $12.00 to $34.00. On average, they expect the company's stock price to reach $22.27 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2023?

CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 225.7% and is now trading at $20.42.
View the best growth stocks for 2023 here
.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 11,910,000 shares, an increase of 9.1% from the October 31st total of 10,920,000 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 5.3 days.
View CymaBay Therapeutics' Short Interest
.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CBAY earnings forecast
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. During the same period in the previous year, the business posted ($0.28) earnings per share.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.12%), Adage Capital Partners GP L.L.C. (3.64%), Jennison Associates LLC (3.22%), Fred Alger Management LLC (1.92%), FMR LLC (1.38%) and Affinity Asset Advisors LLC (1.00%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Kurt Von Emster, Paul T Quinlan and Sujal Shah.
View institutional ownership trends
.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CBAY) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -